Diffuse large B-cell lymphoma · 14 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Busulfan, Fludarabine, Ibritumomab tiuxetan, then allo HSCT Variant #01 | — | R 32 371 | — | — | — | — | — | — |
R-TBI/Cy Variant #01 | — | R 24 768 | — | — | — | — | — | — |
R-BEAM Variant #01 Partial | — | R 22 812 | — | — | — | — | — | — |
Fludarabine, Busulfan, Cyclophosphamide, then allo HSCT Variant #01 | — | R 16 788 | — | — | — | — | — | — |
BeEAM Variant #01 | — | R 16 337 | — | — | — | — | — | — |
Z-BEAM Variant #01 Partial | — | R 12 158 | — | — | — | — | — | — |
BEAM, then allo HSCT Variant #01 Partial | — | R 7 085 | — | — | — | — | — | — |
LEED Variant #01 | — | R 7 064 | — | — | — | — | — | — |
FEAM Variant #01 Partial | — | R 4 294 | — | — | — | — | — | — |
BEAM Variant #01 Partial | — | R 4 294 | — | — | — | — | — | — |
ESHAP Variant #01 | — | R 3 716 | 21d | — | — | — | — | — |
BEAC N/A - secondary systemic drug | — | R 3 241 | — | — | — | — | — | — |
Cyclophosphamide and TBI Variant #01 | — | R 1 176 | — | — | ~90.0 mo | — | — | 1 |
CBV N/A - secondary systemic drug Partial | — | R 43 | — | — | — | — | — | 2 |
14 of 14 regimens shown